A new drug could remove the need for eye injections for the millions of people who suffer from diabetic macular edema (DME), suggested initial data presented by Verseon at last month’s ARVO 2019 annual meeting in Vancouver.

DME is a leading cause of adult blindness, affecting about one in three long-term diabetes patients. The current standards of care for DME are regular injections into the eye – treatments that are associated with side effects and that work poorly or not at all in about half of patients.

Verseon’s development candidate, which is aimed for oral administration, has the potential to fill a large unmet need for both treatment and prevention of DME, said the company.